Education
About Us
Working with TipRanks
Follow Us
Marker Therapeutics (MRKR)
NASDAQ:MRKR
MRKR Analyst Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MRKR Stock 12 Month Forecast
Average Price Target
$9.00
▲(525.00% Upside)
| Highest Price Target$10.00 | Average Price Target$9.00 | Lowest Price Target$8.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Canaccord Genuity
$8
Buy
455.56%
Upside
Reiterated
12/23/25
Analysts Offer Insights on Healthcare Companies: Immunome (NASDAQ: IMNM), Assembly Biosciences (NASDAQ: ASMB) and Marker Therapeutics (NASDAQ: MRKR)We think the heavily pre-treated patient population MRKR is pursuing strengthens their case for accelerated approval from a single arm study, considering the updated guidelines on CAR T approval from the FDA. Many patients receiving MT-601 have already failed CAR T therapy, leaving no effective options, and a clear unmet need that MT-601 can address. MRKR will likely run a randomized study in earlier line patients as a confirmatory study to gain full approval.
H.C. Wainwright
$10
Buy
594.44%
Upside
Initiated
12/08/25
WBB Securities
$12.5
Buy
768.06%
Upside
Reiterated
03/31/25
Brookline Capital Markets
$4
Buy
177.78%
Upside
Initiated
02/10/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Canaccord Genuity
$8
Buy
455.56%
Upside
Reiterated
12/23/25
Analysts Offer Insights on Healthcare Companies: Immunome (NASDAQ: IMNM), Assembly Biosciences (NASDAQ: ASMB) and Marker Therapeutics (NASDAQ: MRKR)We think the heavily pre-treated patient population MRKR is pursuing strengthens their case for accelerated approval from a single arm study, considering the updated guidelines on CAR T approval from the FDA. Many patients receiving MT-601 have already failed CAR T therapy, leaving no effective options, and a clear unmet need that MT-601 can address. MRKR will likely run a randomized study in earlier line patients as a confirmatory study to gain full approval.
H.C. Wainwright
$10
Buy
594.44%
Upside
Initiated
12/08/25
WBB Securities
$12.5
Buy
768.06%
Upside
Reiterated
03/31/25
Brookline Capital Markets
$4
Buy
177.78%
Upside
Initiated
02/10/25
Best Analysts Covering Marker Therapeutics
1 Month
xxx
Success Rate
4/7 ratings generated profit
Average Return
+2.86%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +2.86% per trade.
3 Months
xxx
Success Rate
4/4 ratings generated profit
Average Return
+77.03%
reiterated a xxx
rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +77.03% per trade.
1 Year
Success Rate
3/4 ratings generated profit
Average Return
+1.82%
reiterated a buy rating 9 months ago
Copying Stephen Brozak's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +1.82% per trade.
2 Years
xxx
Success Rate
5/7 ratings generated profit
Average Return
+9.10%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +9.10% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MRKR Analyst Recommendation Trends
Rating
Jun 25
Aug 25
Oct 25
Nov 25
Dec 25
Strong Buy
4
5
4
4
4
Buy
0
0
0
0
0
Hold
1
0
0
0
0
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
5
4
4
4
Each month's total comprises the sum of three months' worth of ratings.
MRKR Financial Forecast
MRKR Stock Forecast FAQ
What is MRKR’s average 12-month price target, according to analysts?
Based on analyst ratings, Marker Therapeutics’s 12-month average price target is 9.00.
What is MRKR’s upside potential, based on the analysts’ average price target?
Marker Therapeutics has 525.00% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MRKR a Buy, Sell or Hold?
Marker Therapeutics has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is Marker Therapeutics’s price target?
The average price target for Marker Therapeutics is 9.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $10.00 ,the lowest forecast is $8.00. The average price target represents 525.00% Increase from the current price of $1.44.
The highest analyst price target is $10.00 ,the lowest forecast is $8.00. The average price target represents 525.00% Increase from the current price of $1.44.
What do analysts say about Marker Therapeutics?
Marker Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of MRKR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.